18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax.
暂无分享,去创建一个
Yoshiharu Yonekura | Takeshi Ishizaki | Tatsuro Tsuchida | Masato Sasaki | Y. Yonekura | T. Tsuchida | Y. Totani | T. Ishizaki | S. Ameshima | I. Miyamori | Yoshiki Demura | Shingo Ameshima | Isamu Miyamori | Shiro Mizuno | Yoshitaka Totani | S. Mizuno | Y. Demura | M. Sasaki
[1] Abass Alavi,et al. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[2] D Delbeke,et al. Prospective investigation of positron emission tomography in lung nodules. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] D. Binns,et al. Positron emission tomography in pulmonary masses where tissue diagnosis is unhelpful or not possible , 2001, Medical Journal of Australia.
[4] M. Younes,et al. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. , 1996, Cancer research.
[5] P. Lewis,et al. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[6] R. Coleman,et al. PET in lung cancer. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[7] V J Lowe,et al. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. , 1995, The Annals of thoracic surgery.
[8] I. Leav,et al. The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to 3H-2-deoxyglucose retention in murine tumor models. , 1996, Nuclear medicine and biology.
[9] L M Hamberg,et al. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[10] S. Larson. Cancer or inflammation? A Holy Grail for nuclear medicine. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[11] J. Luketich,et al. Fluorine-18-fluorodeoxyglucose uptake in pneumonia. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[12] M. Mandelkern,et al. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. , 1996, American journal of respiratory and critical care medicine.
[13] M D Blaufox,et al. PET imaging in oncology. , 2000, Seminars in nuclear medicine.
[14] R L Wahl,et al. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[15] K. Mori,et al. Mediastinal lymph node metastasis from lung cancer: evaluation with Tl-201 SPECT--comparison with CT. , 1994, Radiology.
[16] H. Tonami,et al. Comparison of [(18)F]FDG PET and (201)Tl SPECT in evaluation of pulmonary nodules. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] H. Herzog,et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer , 1999, European Journal of Nuclear Medicine.
[18] A. Alavi,et al. Thallium-201 uptake in lung cancer. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[19] A. Wolf,et al. Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. , 1978, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] S. Suzuki,et al. Partial purification from human mononuclear cells and placental plasma membranes of an insulin mediator which stimulates pyruvate dehydrogenase and suppresses glucose-6-phosphatase. , 1984, Archives of biochemistry and biophysics.
[21] J. Goo,et al. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. , 2000, Radiology.
[22] Scott T. Grafton,et al. PET and [18F]-FDG in oncology: a clinical update. , 1996, Nuclear medicine and biology.
[23] J. Ruhlmann,et al. PET in Oncology , 1999, Springer Berlin Heidelberg.
[24] E. Nitzsche,et al. Evaluation of positron emission tomography with 2‐[18F]fluoro‐2‐deoxy‐D‐glucose for the differentiation of chronic pancreatitis and pancreatic cancer , 1999, The British journal of surgery.
[25] M. Schwaiger,et al. Controlled prospective study of positron emission tomography using the glucose analogue [18F]fluorodeoxyglucose in the evaluation of pulmonary nodules , 1998, The British journal of surgery.
[26] A. Alavi,et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[27] Y. Kawakami,et al. Thallium-201 uptake, histopathological differentiation and Na-K ATPase in lung adenocarcinoma. , 1996, Journal of Nuclear Medicine.
[28] Hiroshi Fukuda,et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection , 2001, European Journal of Nuclear Medicine.
[29] N. Gupta,et al. Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions. , 1998, Chest.
[30] S. Reske,et al. How useful is positron emission tomography for lymphnode staging in non-small-cell lung cancer? , 2000, The thoracic and cardiovascular surgeon.
[31] J M Hoffman,et al. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[32] R Iwata,et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.